CCA
AKRO

Catalyst Capital Advisors’s Akero Therapeutics AKRO Stock Holding History

Catalyst Capital Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-416
Closed -$8K – 418
2019
Q2 		$8K Buy
+416
New +$7.88K ﹤0.01% 328

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's AKRO Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Akero Therapeutics (AKRO) in Q3 2019, closing a stake of 416 shares — an estimated $8K sold.

Catalyst Capital Advisors first reported a position in AKRO in Q2 2019 and held it in 1 quarter. The position peaked at $8K in Q2 2019. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Akero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 416 Akero Therapeutics shares in Q3 2019, an estimated $8K.
  • Catalyst Capital Advisors first reported a position in Akero Therapeutics in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Akero Therapeutics position peaked at $8K in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.